Sign in
CompletedNo phase

Increasing MAT Engagement With Financial Incentives

Key facts

Who runs it
Rowan University
Where
Camden, United StatesSee the site
Trial code
Status
Completed
People taking part
92 people enrolled
Started
27 Jan 2020
Ended
1 Nov 2024
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Contingency management
Record updated
4 April 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Participants at least 18 years of age
  • Participants must be newly enrolled in the Bridge program in the Cooper University ED, with their first clinic appointment scheduled to take place at the Cooper Outreach Clinic within one week of enrollment
  • All subjects must be in good physical health as determined by a physical examination and premenopausal women will have a pregnancy test on the day of the study to rule out pregnancy

Who cannot take part

  • Participants who demonstrate contraindication with Suboxone treatment or who are currently or have recently used other medication-assisted therapies for opioid use disorder
  • Participants who are currently pregnant or breastfeeding or have been diagnosed with a DSM-5 psychiatric condition that might interfere with treatment delivery (e.g., uncontrolled schizophrenia, bipolar disorder, dementia)
  • Participants who are non-English speaking or cannot otherwise provide valid informed consent
  • Individuals who are unable to complete the survey assessments, due to literacy or visual impairments
  • The participant will not be a prisoner

Where in United States

  • Cooper University HospitalCamden, United States

About the trial

What the trial wants to find out

The increased prevalence of opioid use disorder (OUD) and associated overdoses and adverse events has led to a substantial increase in the number of patients being seen at emergency departments (ED). Thus, the ED may be an ideal location for identifying patients in need of OUD treatment and can serve as the first touch point in the OUD continuum of care to promote medication assisted treatment initiation. Contingency management (CM) is an effective method for promoting treatment initiation and adherence that has not been thoroughly evaluated for this purpose. The primary aim of the current study is to develop and assess the effectiveness, acceptability, and feasibility of a protocol for delivering CM to increase combined buprenorphine + nalaxone (referred to as BUP hereafter) initiation and continuous adherence for OUD in an existing ED "bridge" program (e.g., Bridge plus CM; B+CM) relative to standard care. Secondary objectives include identifying behavioral and neuropsychological correlates to treatment outcomes, including delay discounting, reinforcer demand, and neurological soft signs.

The 2 groups in the trial

  • Contingency ManagementTreatment being tested

    Participants in this arm of the study will receive financial incentives for attending their buprenorphine appointments and for being clean from other opioids. Participants in this group will also have up to two rides per week paid for to attend bup appointments.

  • Standard CareNo study treatment, for comparison

    Participants in this group will be treatment as usual and will not receive any incentives for attending their bup appointments or for being opioid abstinent.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Increasing MAT Engagement With Contingency Management Among Individuals With Opioid Use Disorder in an ED Bridge Program
Publications
Record updated
4 April 2025